- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05873543
Het effect van een smartphone-ondersteund hybride hartrevalidatieprogramma bij patiënten met hartfalen. (SHCR-HF)
The aim of this randomized controlled trial is to compare the impact of a case manager-led smartphone-assisted hybrid cardiac rehabilitation program with usual care in patients with HF. Participants will undergo a 12-week program led by a case manager and assisted by a smartphone. The study aims to answer two main questions:
- Is the novel cardiac rehabilitation model feasible for patients with HF?
- Does the intervention group show a significant improvement in exercise capacity and adherence compared to the usual care group?
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Hung-Jui Chuang, MD
- Telefoonnummer: 67034 00886-2-23123456
- E-mail: rexintwo@gmail.com
Studie Locaties
-
-
-
Taipei, Taiwan
- Werving
- Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital
-
Contact:
- Hung-Jui Chuang, MD
- Telefoonnummer: 67034 00886-2-23123456
- E-mail: rexintwo@gmail.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients with heart failure between the ages of 18 and 80 years old.
- NYHA (New York Heart Association) functional classification of 1 to 3.
- Patients must be in a stable condition and under outpatient follow-up.
Exclusion Criteria:
- Patients who have contraindications for exercise according to the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription.
- Patients who are unable to complete cardiopulmonary exercise testing.
- Patients who are unable to follow verbal instructions.
- Patients who are unable to walk independently or pedal a stationary bicycle.
- Patients who are unable to use communication app on a smartphone.
- Patients who already engage in physical activity exceeding the recommended moderate intensity of 150 minutes per week or are currently participating in cardiac rehabilitation.
- Patients who do not provide consent to participate in the trial.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: smartphone-assisted hybrid cardiac rehabilitation (SHCR)
Participants receive a 12-wk case manager-led smartphone-assisted hybrid cardiac rehabilitation with follow-up at 12 week and 6 months. |
The 12-week case manager-led SHCR program includes:
|
|
Geen tussenkomst: Usual care
Participants receive usual care including general education and exercise suggestion. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change of peak oxygen uptake
Tijdsspanne: at baseline, 12 weeks(post-intervention), and 6 months.
|
Peak oxygen uptake will be assessed using cardiopulmonary exercise test before intervention, at 12 weeks (post-intervention), and at 6 months. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Change of 6 minute walking test
Tijdsspanne: at baseline, 12 weeks(post-intervention), and 6 months.
|
6 minute walking test will be performed before intervention, at 12 weeks (post-intervention), and at 6 months. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Adherence to prescribed exercise
Tijdsspanne: 12 weeks(post-intervention)
|
We will evaluate the percentage of completed prescribed exercises at 12 weeks. |
12 weeks(post-intervention)
|
|
Evaluation of Quality of life
Tijdsspanne: at baseline, 12 weeks(post-intervention), and 6 months.
|
The investigators will assess the change in 36-Item Short Form Survey(SF-36). |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Depression
Tijdsspanne: at baseline, 12 weeks(post-intervention), and 6 months.
|
The investigators will assess the change in Patient Health Questionnaire (PHQ-9). The PHQ-9 score ranges from 0-27. Higher scores indicate worsen symptoms. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Anxiety
Tijdsspanne: at baseline, 12 weeks(post-intervention), and 6 months.
|
The investigators will assess the change in Generalized Anxiety Disorder scale (GAD-7). The GAD-7 score ranges 0-21. Higher scores indicate worsen symptoms. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Evaluation of physical activity
Tijdsspanne: at baseline, 12 weeks(post-intervention), and 6 months.
|
The investigators will assess the change in physical activity using International Physical Activity Questionnaire(IPAQ) Taiwan version. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Evaluation of grip strength
Tijdsspanne: at baseline, 12 weeks(post-intervention), and 6 months.
|
The grip strength will be measured using a grip goniometer with the participants seated and the elbow flexed at 90 degrees. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Evaluation of frailty
Tijdsspanne: at baseline, 12 weeks(post-intervention), and 6 months.
|
The investigators will evaluate the change in the Clinical Frailty Scale, which ranges from 1 to 9. Higher scores represent greater illness. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Blood test: Total cholesterol
Tijdsspanne: at baseline, 12 weeks(post-intervention), and 6 months.
|
The Total cholesterol will be tested in the laboratory. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Blood test: LDL
Tijdsspanne: at baseline, 12 weeks(post-intervention), and 6 months.
|
The LDL will be tested in the laboratory. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Blood test: HDL
Tijdsspanne: at baseline, 12 weeks(post-intervention), and 6 months.
|
The HDL will be tested in the laboratory. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Blood test: Triglyceride
Tijdsspanne: at baseline, 12 weeks(post-intervention), and 6 months.
|
The Triglyceride will be tested in the laboratory. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Blood test: NT-proBNP
Tijdsspanne: at baseline, 12 weeks(post-intervention), and 6 months.
|
The NT-proBNP will be tested in the laboratory. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Hung-Jui Chuang, MD, Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 202302009RINC
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .